Search results
...for Patients With Certain Rare Diseases, Pending Medicare Part D Changes | JD Supra
JD Supra· 1 day agoThe Department of Health and Human Services, Office of Inspector General (“OIG”) recently released a favorable advisory opinion, OIG Advisory Opinion No. 24-02 (the “Opinion”) to a nonprofit ...
What is the Medicare Donut Hole and What Are Your Options?
Penny Hoarder via AOL· 6 days agoMedicare can feel complicated. It’s easy to get overwhelmed when sorting through pages of...
Maryland's retirees fear mounting healthcare costs due to prescription drug plan changes
WBFF Fox45 Baltimore· 2 days agoLike many retirees, their medicine cabinet is full, with each pill bottle containing a different...
A ‘slap in the face’: Retired state workers in Maryland outraged by drug plan switch
Baltimore Sun· 2 days agoBefore receiving a heart transplant in 2020, Mark Varner avoided imagining his life too far into the...
Wegovy & other GLP-1 drugs to get coverage under Medicare Part D
AARP· 2 days agoThe FDA recently approved a new use for Wegovy (semaglutide), the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are ...
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
Zacks via Yahoo Finance· 20 hours agoSales of Tyvaso DPI were driven by higher volumes and increased commercialization utilization of the...
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 17 hours agoExelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses...
Q1 2024 Blueprint Medicines Corp Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 11 hours agoImportantly, unlike last year, we expect these patients will be able to stay on therapy for the rest of the year due to changes to the out-of-pocket cap as part of Medicare
Exelixis Inc (EXEL) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
GuruFocus.com via Yahoo Finance· 2 days agoCABOMETYX Net Product Revenues: $376.4 million, including about $6 million in clinical trial sales. Gross to Net Deductions: 32.9% for Q1 2024, primarily due to higher Medicare</ ...
Savvy Senior: Recommended vaccines for Medicare recipients
Daily Press· 7 days agoMy husband and I recently turned 65 and would like to find out which vaccines are recommended and...
